Immutep

IMMUFACT

image Immutep S.A. announces that IMMUFACT® IMP321 has successfully completed Phase I Studies.

Immutep S.A. announced today that its lead product, ImmuFact® IMP321, has successfully completed two large randomised Phase I clinical studies assessing safety, tolerability and immune response in normal healthy volunteers. ImmuFact® IMP321 is a potent natural human T cell immunostimulatory factor designed to amplify the T cell immune response in therapeutic vaccines.

Click to read the complete Press Release (PDF Format).


Published 05/2006 by admin@immutep.com
» Home
© 2002 Immutep, S.A.
Press Release
01/2011 - Immutep and GlaxoSmithKline sign licence agreement for IMP731, a novel therapeutic antibody for the treatment of autoimmune diseases
image Immutep S.A. announced today the execution of a licence agreement ...
09/2010 - Immutep announces final results in phase I/II chemoimmunotherapy trial in metastatic breast cancer.
image Clinical research paper describes IMP321’s potency in achieving ...
05/2010 - Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
image Immutep S.A. announced today that the final results from its Phase ...
01/2010 - Interview Frederic Triebel with PharmaTelevision
01/2010 - ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
image Immutep S.A. announced today the final results from its Phase I/II ...